Federal research into the psychedelic drug Ibogaine as a potential treatment for post-traumatic stress disorder (PTSD) may soon move forward, according to sources familiar with the matter. The drug, derived from the root bark of an African shrub, has shown promise in early studies for its ability to address trauma-related conditions.
Ibogaine, traditionally used in spiritual ceremonies, has attracted scientific interest for its unique neurological effects. Preliminary research suggests it may help ‘reset’ neural pathways associated with traumatic memories. ‘The data from small-scale trials is compelling enough to warrant larger, controlled studies,’ said one official involved in the discussions, speaking on condition of anonymity.
The potential federal involvement comes as the U.S. grapples with rising PTSD cases among veterans and first responders. Analysts note that existing treatments often fall short, creating urgency for alternative therapies. ‘If approved, this could represent a paradigm shift in how we approach trauma treatment,’ a medical researcher told CBS8.
However, significant hurdles remain. Ibogaine is classified as a Schedule I substance in the U.S., and its cardiac risks require careful monitoring. The FDA would need to greenlight any trials, a process that could take years. Still, advocates argue the potential benefits outweigh the risks for patients with limited options.
Looking ahead, the research could pave the way for broader acceptance of psychedelic-assisted therapies. Several states have already decriminalized psilocybin and MDMA for medical use, signaling shifting attitudes toward once-stigmatized substances.